CA2383615A1 - Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus - Google Patents

Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus Download PDF

Info

Publication number
CA2383615A1
CA2383615A1 CA002383615A CA2383615A CA2383615A1 CA 2383615 A1 CA2383615 A1 CA 2383615A1 CA 002383615 A CA002383615 A CA 002383615A CA 2383615 A CA2383615 A CA 2383615A CA 2383615 A1 CA2383615 A1 CA 2383615A1
Authority
CA
Canada
Prior art keywords
patient
her2
neu
cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383615A
Other languages
English (en)
Inventor
Alexander Gaiger
Martin A. Cheever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383615A1 publication Critical patent/CA2383615A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de détection et de traitement de malignités associées aux virus au moyen des séquences Her2/neu. Les Her2/neu peuvent se présenter comme des polypeptides ou des polynucléotides.
CA002383615A 1999-09-22 2000-09-22 Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus Abandoned CA2383615A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40444399A 1999-09-22 1999-09-22
US09/404,443 1999-09-22
PCT/US2000/026110 WO2001021192A2 (fr) 1999-09-22 2000-09-22 Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus

Publications (1)

Publication Number Publication Date
CA2383615A1 true CA2383615A1 (fr) 2001-03-29

Family

ID=23599624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383615A Abandoned CA2383615A1 (fr) 1999-09-22 2000-09-22 Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus

Country Status (4)

Country Link
EP (1) EP1214595A2 (fr)
AU (1) AU7710300A (fr)
CA (1) CA2383615A1 (fr)
WO (1) WO2001021192A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1490801A (en) * 1999-11-15 2001-05-30 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
AU2744201A (en) * 1999-12-29 2001-07-09 Corixa Corporation Murine neu sequences and methods of use therefor
CA2407556C (fr) 2000-05-19 2011-06-21 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
WO2002013847A2 (fr) * 2000-08-14 2002-02-21 Corixa Corporation Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
EP1613736A4 (fr) * 2003-03-11 2007-04-11 Dana Farber Cancer Inst Inc Inhibition de la pathogenese virale
BRPI0518104B8 (pt) 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
CA2677108A1 (fr) 2007-03-02 2008-09-12 Genentech, Inc. Element de prevision de la reponse a un inhibiteur de her
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
CA2798837A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013063229A1 (fr) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Traitement par un agent de ciblage de her2 dans des cancers non amplifiés par her2 ayant des cellules souches cancéreuses exprimant her2
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2017194554A1 (fr) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polythérapies pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
EP0711565B1 (fr) * 1994-11-10 1998-08-26 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibition de la croissance des cellules leucemiques par ciblage de la protéine HER-2

Also Published As

Publication number Publication date
EP1214595A2 (fr) 2002-06-19
AU7710300A (en) 2001-04-24
WO2001021192A2 (fr) 2001-03-29
WO2001021192A3 (fr) 2001-08-16

Similar Documents

Publication Publication Date Title
EP1183348B1 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
EP1141290B1 (fr) Compositions et procedes destines a la therapie et au diagnostic du cancer de l'ovaire
EP1349870B1 (fr) Compositions utilisés dans la thérapie et le diagnostic du cancer des ovaires
US6962980B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1169347B1 (fr) Composes et procedes de therapie et de diagnostic du cancer du poumon
WO2002013847A2 (fr) Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
CA2383615A1 (fr) Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus
AU2001276973A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20010055596A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
US20020150588A1 (en) SPAS-1 cancer antigen
JP4806124B2 (ja) 乳癌の処置および診断のための組成物ならびにそれらの使用方法
JP2002540789A5 (fr)
WO2001051513A2 (fr) Sequences associees a une tumeur ovarienne
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
NZ567750A (en) Compositions and uses for cancer therapy
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US6933363B1 (en) Compositions and methods for therapy and diagnosis of lung cancer
ES2350041T3 (es) Composiciones y métodos para la terapia y diagnóstico del cáncer de ovarios.
US20030157119A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
US20030045468A1 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
AU2007216683B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
ES2315296T3 (es) Composiciones para la terapia uy el diagnostico del cancer ovarico.
WO2001027276A2 (fr) Sequences de tumeur du sein et leurs procedes d'utilisation

Legal Events

Date Code Title Description
FZDE Discontinued